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Abstract 
 
This paper estimates the marginal willingness-to-pay for attributes of a hypothetical HIV 
vaccine using discrete choice modeling. 
 
We use primary data from 326 respondents from Bangkok and Chiang Mai, Thailand, in 
2008-2009, selected using purposive, venue-based sampling across two strata. Participants 
completed a structured questionnaire and full rank discrete choice modelling task 
administered using computer-assisted personal interviewing. The choice experiment was used 
to rank eight hypothetical HIV vaccine scenarios, with each scenario comprising seven 
attributes (including cost) each of which had two levels. The data were analyzed in two 
alternative specifications: (1) best-worst; and (2) full-rank, using logit likelihood functions 
estimated with custom routines in Gauss matrix programming language.  
 
In the full-rank specification, all vaccine attributes are significant predictors of probability of 
vaccine choice. The biomedical attributes of the hypothetical HIV vaccine (efficacy, absence 
of VISP, absence of side effects, and duration of effect) are the most important attributes for 
HIV vaccine choice. On average respondents are more than twice as likely to accept a 
vaccine with 99% efficacy, than a vaccine with 50% efficacy. This translates to a willingness 
to pay US$383 more for a high efficacy vaccine compared with the low efficacy vaccine. 
 
Knowledge of the relative importance of determinants of HIV vaccine acceptability is 
important to ensure the success of future vaccination programs. Future acceptability studies 
of hypothetical HIV vaccines should use more finely-grained biomedical attributes, and could 
also improve the external validity of results by including more levels of the cost attribute. 
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1. Introduction 
 
A safe, efficacious and accessible prophylactic vaccine for HIV remains elusive despite 
promising results in some recent trials [1-3]. Nevertheless, with an estimated 2.5 million new 
HIV infections each year [4], a vaccine is the most promising means of controlling the 
epidemic. Ongoing research on candidate vaccines will continue to require the support of 
thousands of volunteers for enrolment in Phase II and Phase III vaccine trials. An increasing 
focus on implementation science in health care, and recognition of the significant gap 
between efficacy in clinical trials and effectiveness in the real world in the case of already 
licensed vaccines (e.g., HBV, HPV), also raises the importance of research that looks beyond 
clinical trials [5-6].  To date there have been relatively few investigations of the potential 
uptake of future HIV vaccines, particularly outside the United States [7]. An understanding of 
the factors associated with vaccine acceptability, particularly within high-risk groups, and the 
vaccine attributes or characteristics that contribute to acceptability, is important to ensure 
uptake of a future vaccine. 
 
 Vaccine acceptability is a measure of potential users’ judgment of the satisfactoriness of 
the vaccine and their willingness to be vaccinated [7]. In quantitative studies, vaccine 
acceptability is typically measured as a dichotomous yes/no response to a willingness to be 
vaccinated question (e.g. see [8-9]), or measured on a Likert scale (e.g. see [10-11]) or as a 
probability of accepting vaccination (e.g. see [12-13]). 
 
 An alternative to investigating vaccine acceptability is to directly consider the willingness-
to-pay (henceforth WTP) for it by potential recipients. Few studies have adopted a contingent 
valuation approach to estimate WTP for hypothetical HIV vaccines (e.g. see [14-16]). This 
approach involves presenting the respondents with one or a small number of scenarios that 
include a price for a hypothetical vaccine of given attributes, then adjusting the price in 
several steps in order to determine the respondent’s maximum willingness-to-pay for each 
vaccine scenario [17]. The advantage of these studies is that they provide a more direct way 
to estimate the potential demand for a future HIV vaccine, rather than simply the vaccine’s 
acceptability; more work of this type is clearly needed [18]. 
 
 In most studies of vaccine acceptability, the vaccine-specific attributes determining its 
acceptability are typically investigated by presenting each survey respondent with a number 
of different vaccine alternatives, each of which has different attributes. Some studies have 
presented a limited number of scenarios with few vaccine attributes (e.g. see [19]), but most 
have used a more complex experimental design involving conjoint value analysis (e.g. see 
[11,20,21]). In conjoint value analysis, the respondent is presented with a series of cards, 
each of which describes an alternative hypothetical vaccine on the basis of its attributes. 
Respondents disclose their preferences by ordering the cards (alternative vaccines) from best 
to worst. They are then asked to rate the scenario on each card in terms of acceptability, using 
one of the measures noted above. 
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 To investigate the determinants of vaccine acceptability, most studies then convert the 
vaccine acceptability variable into either a linear form for ordinary least squares regression 
analysis (e.g. see [22-23]) or into a dichotomous variable for logistic regression analysis (e.g. 
see [24]). In either case vaccine acceptability is the dependent variable and respondent 
characteristics and hypothetical vaccine attributes may be used as explanatory variables (e.g. 
see [20]). Newman and Logie [7] conducted a systematic review and meta-analysis of HIV 
vaccine acceptability studies of these and other types, and found that the acceptability of a 
hypothetical vaccine varied between 37.2 and 94.0 on a 100-point linearised scale, with a 
weighted mean of 65.6, and that vaccine acceptability was substantially higher for high 
efficacy versus moderate efficacy vaccines. They also found that effect sizes were largest 
(and significant) for efficacy, non ‘risk group’ membership, pragmatic obstacles (e.g. 
transportation and access to health facilities), and vaccine cost. 
 
 The key problem with the linearised or dichotimised vaccine acceptability approach 
described above is that conventional choice-based conjoint value analysis, as conducted in 
these studies, does not have a natural mapping into ordinal utility theory and hence into 
measures of economic welfare change. The analysis implicitly uses vaccine acceptability as 
an indicator of cardinal utility, which is not necessarily how the respondent interprets 
acceptability in their decision making process. Furthermore, because in most studies vaccine 
cost, if included, is effects coded, the opportunity for a more detailed consideration of the 
marginal willingness-to-pay of different vaccine attributes is lost. This is in spite of the 
recognition of the advantage of including cost in order to represent preference between 
attributes in monetary terms [25]. 
 
 An arguably more appealing approach to assessing end user preferences is provided by 
interpreting observed choices by means of utility-theoretic frameworks [26-27]. For example, 
using a random utility model approach, the marginal effects on utility levels of changes in 
attributes (e.g., efficacy, duration of effect) of hypothetical vaccines can be identified and 
estimated. This enables researcher to evaluate the acceptability of different vaccine profiles 
(or combinations of vaccine attributes) in the target population. When one of the attributes 
evaluated is the cost of the hypothetical vaccine then the trade-off between other attributes 
and cost can be evaluated in terms of probability of acceptance at any given cost within the 
range explored [28]. In other words, commonly accepted economic estimates of welfare 
change (consumer surplus and marginal willingness to pay) for separate vaccine attributes 
can be identified and estimated from the ranking data when handled as discrete choices 
between mutually exclusive competing alternatives [29]. A full ranking of seven alternatives 
can, for example, be interpreted as a sequence of six discrete choices [30]. The first ranked 
alternative is chosen from seven, the second ranked from six, and so on until the alternative 
ranked second to the last is selected from two remaining attributes. There exists a vast 
literature on choice modelling based on random utility theory that can be used to analyse 
ranking data of this sort [30,31]. The category of models of reference includes the 
multinomial logit and probit models [32,33] and its very numerous extensions [34]. Among 
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the major advantages of applying the random utility approach to choice-based conjoint 
analysis is its efficiency and precision. 
 
 In this paper, we adopt the random utility approach to derive estimates of the marginal 
willingness-to-pay for different attributes of a hypothetical HIV vaccine among men who 
have sex with men (MSM), male sex workers, and transgender women in Thailand. 
 
2.  Methods 
 
Based on preliminary qualitative data collection and previous studies of vaccine acceptability, 
eight hypothetical HIV vaccine scenarios were constructed. Each scenario featured a bundle 
of seven dichotomous vaccine attributes: (1) 99% versus 50% efficacy; (2) no versus minor 
side effects (specifically temporary body aches, skin rash and fevers); (3) 10-year versus one-
year duration of protection; (4) vaccine-induced seropositivity (VISP) (wherein vaccinated 
individuals would subsequently test antibody positive for HIV) or not; (5) administered at 
private versus public hospitals; (6) high versus low social saturation (the proportion of the 
population already vaccinated); and (7) vaccine cost of THB100 versus THB2500 (about 
US$3 versus US$75). Eight scenarios with seven attributes (including cost) were chosen in 
order to keep the cognitive task manageable for respondents. Formative qualitative research 
was used to decide on the final attributes and levels for inclusion. A fractional factorial 
orthogonal design allowing only for main effects was used to develop the eight scenarios, 
based on a Plackett-Burman design [35]. We note that out-of-pocket costs for medical 
procedures, including vaccines, are not unusual in Thailand – thus the problem of 
respondents’ misinterpretation of the cost variable [36,37] is less likely to arise, since the 
respondents should understand the true financial consequence of their choices. 
 
 Respondents (aged 18 years or over) were selected using purposive, venue-based sampling 
[38] across two strata in Bangkok and Chiang Mai cities. The first stratum included gay 
entertainment venues such as gay strip clubs, movie theatres, massage parlours, and sex 
motels. The second stratum included community-based organisations providing HIV 
prevention services to high-risk groups such as MSM, male sex workers, and transgender 
women. Data were collected from 326 respondents between March 2008 and February 2009 
using Computer-Assisted Personal Interviewing [39]. The median age of respondents was 27 
years; 67.2% were male, 20.2% female, and 12.6% transgender; 63.2% self-identified as gay 
or homosexual, 4.3% bisexual, and 32.2% heterosexual. The median monthly income of 
respondents was THB11,197 (US$345). Further details on data collection are available in 
Newman et al. [40]. The research was approved by the institutional review boards of UCLA 
and the University of Toronto, and written informed consent was obtained from all 
respondents. 
 
 Each respondent was first presented with eight laminated cards, one with each vaccine 
scenario, and asked to rank the eight scenarios, from the ‘best’ vaccine to the ‘worst’ vaccine. 
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The respondents did this by first selecting the vaccine scenario they thought represented the 
‘best’ vaccine, then selecting the vaccine scenario they though represented the ‘worst’ 
vaccine. Finally, they were asked to arrange the remaining six scenarios in order between 
their chosen best and worst scenarios. This procedure leads to a complete rank ordering of the 
scenarios, as well as a definite procedure by which the respondents arrive at their ranking that 
can be exploited in the analysis. There was no opt-out option, i.e. respondents were forced to 
choose their ranking with no alternative option which is not to be vaccinated at all (a ‘forced 
choice’ experiment). Our results therefore reflect the probability of a respondent choosing a 
vaccine scenario in a forced choice rather than the probability of that scenario being 
acceptable to the respondent. Given that one of the attributes in the conjoint scenarios is cost 
(price) of the vaccine, we can use this to evaluate the trade-off between other attributes and 
cost in terms of probability of acceptance at any given cost. Furthermore, because this 
procedure is a forced choice, methods of estimating monetary valuations remain valid, as 
noted by Ryan [41]. 
 
 Rank ordered choice data lend themselves to various alternative specifications. In the first 
specification, the data were fitted to a multinomial logit likelihood function using only the 
best and worst choices of each respondent [42]. In this specification, the ‘best’ alternative is 
chosen from all eight scenarios, but the ‘worst’ alternative is chosen from the seven 
remaining alternatives (i.e. excluding the ‘best’). The literature proposing this approach 
argues that focus on extremes of preference rankings is cognitively less difficult or costly for 
the respondent and hence the utility functions are less affected by error variance. In the 
second specification, the data were fitted to a logit likelihood function using the full ranking 
data provided by the respondents using the rank-exploded logit model [30]. In this second 
specification, the ranking is interpreted as a sequence of seven discrete choices - the ‘best’ 
ranked alternative is chosen from all eight scenarios, the ‘worst’ is chosen from the remaining 
seven, the ‘second best’ is chosen from the remaining six, and so on until the ‘fourth best’ 
scenario is selected from two remaining scenarios. This specification follows the procedure 
that respondents were asked to follow, in first determining the best, then the worst alternative, 
before ranking the remaining six scenarios. We assume that respondents follow the same 
procedure (best, worst) throughout. Recent research in alternative utility coding for full-rank 
choice sets suggests that repeated best is consistent with what a large fraction of respondents 
appear to be naturally doing in their selection. It also suggests that other ways to code utilities 
(e.g. repeated worst) produce mostly insignificant differences in estimated value for the 
utility coefficients [43,44]. In both specifications only vaccine attributes, inclusive of cost, 
were used as attributes of the systematic component of the utility function. All attribute levels 
were dummy-coded with the exception of cost. 
 
 Finally, we were able to evaluate the trade-off between other attributes and cost in terms 
of probability of acceptance at any given cost. The marginal willingness-to-pay for each 
vaccine attribute was estimated by taking the ratio of the estimated coefficient on each 
vaccine attribute to the estimated coefficient on cost. From these marginal willingness-to-pay 
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estimates, a mean willingness to pay and associated confidence interval can be estimated for 
any combination of vaccine attributes. 
 
 Two respondents recorded invalid rankings, reducing the final sample size to 324. The 
marginal effects on utility of the vaccine attributes were estimated using maximum likelihood 
estimation routines coded in Gauss matrix programming language (Aptech Systems). 
Marginal effects were converted to odds ratios to aid interpretation. 
 
3.  Results 
 
The results from the best-worst specification, in terms of estimated impact on vaccine choice, 
are presented in Table 1. Efficacy is the vaccine attribute with the greatest marginal effect on 
choice – on average respondents are more than three times as likely to choose (odds ratio 
3.432) a vaccine with 99% efficacy, than a vaccine with 50% efficacy. Absence of moderate 
side effects more than doubles the probability of choice, while probability of choice is almost 
doubled by the absence of VISP. Duration and social saturation both significantly increase 
the probability of choice, but venue for vaccination is statistically insignificant. 
 
Table 1: Factors affecting probability of vaccine choice – best-worst specification 
Attribute Odds Ratio  Estimate  Std. Error  P-value  
Efficacy  3.432  1.2332  0.0951  <0.0001*** 
(Absence of) VISP 1.907  0.6456  0.0853  <0.0001***  
(Absence of) Side Effects  2.138  0.7597  0.0862  <0.0001*** 
Cost  0.226  -1.4857  0.3472  <0.0001*** 
Social Saturation (Majority)  1.180  0.1658  0.0823  0.0438** 
Duration  1.508  0.4105  0.0838  <0.0001*** 
Venue (Private)  0.983  -0.0168  0.0541  0.7563 
*** significant at the 1% level; ** significant at the 5% level; * significant at the 10% level. 
 
The results from the full rank specification are similar, as shown in Table 2. Efficacy has the 
greatest marginal effect on choice, but in this specification VISP is the second most important 
attribute. Social saturation and venue for vaccination have small, but statistically significant 
(although only at the 10% level for venue), effects on vaccine choice. 
 
Table 2: Factors affecting probability of vaccine choice – full rank specification 
Attribute Odds Ratio  Estimate  Std. Error  P-value  
Efficacy  2.238  0.8055  0.0487  <0.0001*** 
(Absence of) VISP 1.933  0.6590  0.0486  <0.0001***  
(Absence of) Side Effects  1.506  0.4094  0.0466  <0.0001*** 
Cost  0.523  -0.6482  0.1926  0.0008*** 
Social Saturation (Majority)  1.140  0.1311  0.0474  0.0057*** 
Duration  1.263  0.2334  0.0473  <0.0001*** 
Venue (Private)  1.081  0.0782  0.0460  0.0895* 
*** significant at the 1% level; ** significant at the 5% level; * significant at the 10% level. 
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 The results from both specifications, when converted to marginal willingness-to-pay, are 
shown in Table 3, along with the 95% confidence interval for the estimates (derived using the 
Krinsky-Robb procedure [45], with 10,000 replications). These results are similar to those 
reported in the earlier two tables. Efficacy has the greatest contribution to willingness-to-pay, 
with respondents on average willing to pay US$244 more for a high (99%) efficacy than low 
(50%) efficacy vaccine in the best-worst specification, and willing to pay US$383 more for a 
high efficacy vaccine in the full rank specification. This willingness-to-pay for high efficacy 
is particularly high, given that the mean monthly income of the sample was US$375 per 
month. 
 
 The average willingness-to-pay for an HIV vaccine with any combination of attributes can 
also be derived from Table 3. For instance, the willingness-to-pay for the most advantageous 
(in the eyes of respondents on average) HIV vaccine (i.e. a vaccine with 99% efficacy, no 
side effects, no VISP, a 10-year duration, where the majority have also been vaccinated, and 
delivered at a private hospital) is US$1100.50 (with a 95% confidence interval of between 
US$684.82 and US$2544.18). The willingness-to-pay for a lower cost or less optimal vaccine 
which might correspond more closely to early vaccine rollout (e.g. 50% efficacy, minor side 
effects, no VISP, 10-year duration, where the majority have not been vaccinated, and 
delivered at a private hospital) is US$461.09 (with a 95% confidence interval of between 
US$281.78 and US$1103.67). 
 
Table 3: Marginal willingness-to-pay for vaccine attributes 
Attribute 
Best-Worst Full-Rank 
WTP ($US) 
(95% C.I.) 
WTP ($US) 
(95% C.I.) 
Efficacy  256.11 
(167.88–482.61) 
382.65 
(240.50–900.90) 
(Absence of) VISP  134.09 
(83.14–252.70) 
313.09 
(192.80–745.82) 
(Absence of) Side Effects  157.78 
(98.62–303.14 
194.50 
(116.21–466.76) 
Social Saturation (Majority)  34.44 
(1.02–89.03)  
62.27 
(17.51–172.07) 
Duration  85.26 
(42.34–179.42)  
110.86 
(56.52–269.94) 
Venue (Private)  -3.49 
(-28.64–20.90)  
37.14 
(-6.17–117.95) 
 
 
4.  Discussion  
 
In general, we found that the biomedical attributes of a hypothetical HIV vaccine (efficacy, 
absence of VISP, absence of side effects, and duration of effect) were the most important 
attributes to respondents, in the sense that these were the vaccine attributes that they were 
willing to pay the most for. Other attributes (social saturation, venue for vaccination) were 
valued less by respondents. These results are important for consideration prior to the rollout 
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of any future HIV vaccine. A vaccine with low efficacy, and/or which results in vaccine-
induced seropositivity or moderate side effects, would have significantly lower acceptability 
among high-risk groups, and lead to lower uptake and reduced impact on HIV transmission 
within the group. However, the vaccine attributes investigated here were necessarily coarse, 
especially efficacy (99% versus 50%). While we can say that respondents were willing to pay 
significantly more for 99% efficacy as opposed to 50%, we cannot say whether, for instance, 
a reduction to 80% efficacy would significantly affect the acceptability of a future HIV 
vaccine. Future studies should look at more fine-grained efficacy and duration of protection 
attributes, in order to determine whether small changes in these attributes are important to 
potential vaccine recipients, particularly as it is unlikely that a vaccine with efficacy of 
anywhere close to 99% will become available for some time. 
 
 The signs on the coefficients for social saturation are interesting, although a priori we had 
no strong expectation for a given sign on the coefficient. The signs on the social saturation 
coefficients imply that respondents are willing to pay more for (and hence more willing to 
accept) a vaccine where a majority of the population has already been vaccinated. This 
contrasts with Heal and Kunreuther [46], who showed that the incentives to be vaccinated 
reduce as more of the population become vaccinated, because the private benefits of 
individual vaccination reduce. This ‘free-riding’ explanation does not appear to hold in our 
data. This may be because this study is based on stated preference data and not actual 
vaccination behavior. Alternatively, it may be that people are more likely to get vaccinated 
because of the perceived benefits to others (altruism), or because the number of people who 
have already decided to become vaccinated provides a signal that the decision to become 
vaccinated is a good decision (‘bandwagoning’) [47]. While altruism is consistent with 
Theravada Buddhism, the predominant religion in Thailand, we have no way of directly 
testing whether it is altruism or bandwagoning that is driving the coefficient on social 
saturation in this data. However, this result is clearly important because social saturation has 
a small but significant effect on vaccine acceptability. Future studies should consider in more 
detail whether and through which mechanism or mechanisms social saturation impacts on 
vaccine acceptability. For example, socio-cultural factors such as communitarian norms or 
stigma [40,48] should be investigated. If this result proves to be a general result, then it 
would provide a justification for broad government-subsidized vaccination when a safe, 
efficacious vaccine becomes available. 
 
 In low- and middle-income countries, it is particularly important to consider the impact of 
cost; an increase from $3 to $75 resulted in nearly 50% lower odds of vaccine acceptability 
among men and transgender women in Thailand at high risk of HIV exposure. From the 
perspective of lifetime costs of HIV treatment, estimated at $500,000 [49,50], this suggests 
that government and privately funded subsidies could have a substantial and cost-effective 
impact on the epidemic by increasing vaccine uptake. In this context, an actual vaccine priced 
at the estimated willingness-to-pay for the hypothetically best vaccine, absent cost subsidies, 
might result in low uptake among high-risk communities, thereby substantially reducing the 
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effectiveness of the vaccine on a population level. This paper used only two levels of the cost 
attribute, which were spaced far apart in terms of affordability for respondents. Future studies 
could improve the external validity of results by including more levels of the cost attribute.  
 
 Our analysis using random utility models clearly shows that efficacy is the most important 
vaccine attribute, both in terms of the probability of vaccine acceptability and in terms of 
marginal willingness-to-pay. This result is different from those obtained with the same data 
using conjoint value analysis based on linearised acceptability with ordinary least squares 
regression (see [40]), where VISP was found to be the most important attribute, followed by 
efficacy and side effects. The results from our paper (primacy of efficacy) resonate with 
results from previous studies from North America (e.g. see [11]). While VISP was also found 
to be an important vaccine attribute in the present analysis, the difference between the two 
analyses demonstrates a potential for bias when less information about ranking of attributes is 
used and different assumptions are invoked in the analysis of data. On a substantive level, the 
importance of VISP might be mitigated with broad educational campaigns delivered in 
tandem with future vaccines, and may abate once an HIV vaccine achieves broad coverage 
(such that many of one’s peers also test positive due to the vaccine) along with easy access to 
tests that detect the difference between VISP and actual HIV infection [40].   
 
 The discovery of a safe and efficacious HIV vaccine will be a momentous event for global 
public health. Further evidence that supports bridging the gap between vaccine availability 
and public utilization [51], such as that reported here, is crucial to the success of future HIV 
vaccines in reversing the epidemic.    
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